Regencell Bioscience Holdings Ltd RGC

$RGC HUGE Shortsqueeze potential on Healthcare Counter

[sungrin1309]

Regencell Bioscience Limited’s (NASDAQ:RGC) stock that has seen a good rise of over 300% since taking the company IPO in July 2021. The company is a bioscience **healthcare** company that focuses on heavily on R&D and commercialisation of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.

Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).

As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.

[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]

For Short volume available, to look up at https://fintel.io/ss/us/rgc#